For decades, acne management has operated within an antibacterial framework including, topical antimicrobials, oral antibiotics, and surface exfoliation anchored by the assumption that suppressing Cutibacterium acnes is sufficient to control disease. The AAD guidelines continue to recommend benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline as first-line therapy." The clinical consequence is familiar: patients cycle through agents, achieve transient improvement, and return with recurrence.
The contemporary pathogenesis model is multifactorial, with sebaceous hyperactivity positioned as the most clinically actionable upstream driver.2,2 Androgen-driven sebum overproduction creates the follicular environment that permits keratinocyte obstruction, supports C. acnes proliferation, and elicits the inflammatory response visible at the lesion level. Recent microbiome research has reframed C. acnes’ role: bacterial burden is not significantly different between acne-prone and healthy skin, what differs is phylotype composition. Virulent phylotypes (notably IA1) are overrepresented in acne lesions, biofilm formation is more frequent, and these strains preferentially trigger TLR-mediated innate immune activation within the pilosebaceous unit.4 But the variable that most powerfully governs whether the cascade activates is sebaceous output.
Related: Nano-Pulse Stimulation for Sebaceous Hyperplasia
The strongest evidence for this hierarchy comes from pharmacology. Isotretinoin and hormonal therapy, the two most powerful interventions in acne, both act primarily on sebum.’ Antibiotic regimens, which act on bacteria and inflammation while leaving sebum untouched, produce the recurrence pattern that defines so much of clinical practice.
This is the clinical premise behind the Aerolase Neo Elite, which has acquired one of the deepest evidence bases for any energy-based acne modality; a double-blind RCT, a prospective clinical evaluation, a 50-dermatologist real-world field survey, a resistant-case series, and a combination protocol with low-dose isotretinoin.
MECHANISM OF ACTION
The sebaceous gland is an active immunoregulatory organ, not a passive lipid factory - producing hormones, neuropeptides, antimicrobial peptides, and pro- and anti-inflammatory mediators.6 Therapeutic modulation acts simultaneously on lipid output and on its role in the dermal inflammatory environment.
The Neo Elite delivers 1064nm Nd:YAG energy in a 650-microsecond pulse: long enough for therapeutic dermal penetration, short enough to minimize epidermal thermal diffusion - the basis of its safety profile across all Fitzpatrick skin types? Three coordinated effects follow: photothermal heating normalizes sebaceous output; thermal energy within the follicular unit disrupts C. acnes without antibiotic exposure; and vascular coagulation suppresses the inflammatory environment sustaining lesion activity.8 All three occur from the same wavelength and pulse profile, without separate device parameters, a single treatment engaging the full pathogenic triad.
Related: The Ultimate Solution for Post-Acne Hyperpigmentation and Scarring
THE CLINICAL EVIDENCE
Foundational RCT. Kesty and Goldberg’s 2020 double-blind RCT demonstrated 75% GAGS improvement in the laser-treated cohort at three months versus 25% in the sham group.8
Prospective evaluation in moderate to severe disease. In Dr. Saedi’s study, 23 patients (57% moderate, 39% severe acne) across Fitzpatrick II-VI over five treatments at two-week intervals.9 Median lesion count reduction reached 84% at end of treatment and 87% at the 90-day follow-up - continued improvement after the final session, consistent with sustained sebaceous down regulation rather than temporary suppression. IGA improved from 3.2 to 1.2 by week six with no regression through follow-up. Patient satisfaction reached 95% at 30 days; patient-reported self-esteem improved from 35% to 90% by week six.2
Photo Courtesy of Nina Harry, FNP-BC
Photo Courtesy of Zoe Flor, DNP, FNP-C
Resistant cases. 10 Fitzpatrick I-IV patients who had failed standard regimens; meaningful clearance was achieved in three to seven sessions.11
Combination with low-dose isotretinoin. Dr.Gold’s protocol produced 70.3% reduction in inflammatory lesions and a GAGS improvement greater than 5.5 points - both modalities acting additively on sebaceous output.12
TOLERABILITY AND SAFETY
Median VAS pain score was 2.0, with 76% of patients in the 1-3 range; 66% of respondents report fewer than 10% non-compliant patients.10 For adolescent populations, where compliance attrition has constrained procedural options, this is a meaningful finding.
On safety: post-inflammatory hyperpigmentation has been the rate-limiting concern for energy-based treatment in Fitzpatrick IV-VI patients. The 650-microsecond pulse duration minimizes epidermal thermal accumulation, enabling calibrated fluence by skin type? Various studies have separately documented the platform’s skin-of-color safety profile across multiple indications.7
SKIN-OF-COLOR SAFETY: A MECHANISM-DRIVEN ADVANTAGE
The safety profile across Fitzpatrick skin types is not incidental, it is a direct consequence of the 650-microsecond pulse architecture. Conventional Nd:YAG platforms operating in the millisecond range deposit thermal energy over a duration that permits lateral diffusion into the epidermis, creating a meaningful risk of dyspigmentation in melanin-rich skin. The 650-microsecond pulse sits below the thermal relaxation time of the epidermis while remaining above that of the therapeutic targets; the sebaceous gland and microvasculature. The result is selective dermal heating with minimal epidermal thermal accumulation, enabling the clinician to titrate fluence to skin type without the dyspigmentation ceiling that has historically constrained energy-based acne treatment in darker phototypes. This is not a workaround or a modified protocol for Fitzpatrick IV-VI patients - it is the same treatment, with the same mechanism, calibrated to the same therapeutic endpoints.
ANCILLARY OUTCOMES
Beyond lesion clearance, improvement in post-inflammatory hyperpigmentation and erythema (90%), acne scarring (82%), skin tone and texture (80%), reduced oiliness (70%), and visible skin tightening (52%) was seen. The 70% reporting reduced oiliness is the clearest real-world signal of sustained sebaceous downregulation - consistent with the durable 87% lesion reduction at 90 days.9
ADDRESSING POST-INFLAMMATORY SCARRING
The international consensus supports fractional ablative and non-ablative platforms as standards of care for atrophic scar remodeling.13 The Aerolase Hybrid Fractional Lens delivers fractional ablation with controlled thermal renewal for scar architecture and dermal remodeling. Used in sequence with the Neo Elite, a practice can manage the full clinical arc of acne beginning with the active disease through post-inflammatory sequelae, on a single platform.
MANAGING THE FULL ACNE ARC ON A SINGLE PLATFORM
As we’ve all known, acne is rarely presented as a single clinical problem. The active disease phase of inflammatory papules, pustules, nodules eventually resolves, incompletely, into a sequelae phase defined by post-inflammatory hyperpigmentation, persistent erythema, and atrophic scarring. These are not separate conditions requiring separate referrals or separate devices; they are stages of the same pathological process in the same patient. The Neo Elite’s ancillary outcomes data reflects this reality: 90% of respondents reported improvement in PIH and erythema alongside lesion clearance, and 82% reported improvement in acne scarring, outcomes generated not by a separate protocol but by the same 650-microsecond 1064nm treatment targeting active disease.1?
For deeper atrophic scar remodeling, the Aerolase Hybrid Fractional Lens extends the platform’s capability: fractional ablation with controlled thermal renewal addresses scar architecture and dermal collagen reorganization at a structural level. The clinical and operational implication is clear: a practice equipped with both modalities can manage a patient from first breakout through full skin restoration without routing them to a separate device, a separate provider, or a separate treatment philosophy.
IMPLICATIONS FOR THE TREATMENT PARADIGM
The evidence supports positioning the Neo Elite not as adjunctive, but as a primary therapeutic modality: efficacy across severity tiers, durability through 90 days and beyond, safety across Fitzpatrick skin types, tolerability suited to adolescent populations, and a mechanism that addresses sebaceous output, bacterial proliferation, and inflammation in a single coordinated treatment.
The patient pattern that defines so much of clinical acne practice recurring breakouts on otherwise adequate regimens is a downstream consequence of treating bacteria without treating sebum. Treating sebum is what the Neo Elite was engineered to do.
Moderate Acne
Photo Courtesy of Dr. Z Teo
REFERENCES
1. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-1006.e30.
2. Eichenfield DZ, Sprague J, Eichenfield LF. Management of acne vulgaris: a review. JAMA. 2021;326(20):2055-2067.
3. Tan JKL, Stein Gold LF, Alexis AF, Harper JC. Current concepts in acne pathogenesis: pathways to inflammation. Semin Cutan Med Surg. 2018;37(3S):S60-S62.
4. Dreno B, Dagnelie MA, Khammari A, Corvec S. The skin microbiome: a new actor in inflammatory acne. Am J Clin Dermatol. 2020;21(Suppl 1):18-24.
5. Mayslich C, Grange PA, Dupin N. Cutibacterium acnes as an opportunistic pathogen: an update of its virulence-associated factors. Microorganisms. 2021;9(2):303.
6. Zouboulis CC, Coenye T, He L, et al. Sebaceous immunobiology: skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations. Front Immunol. 2022;13:1029818.
7. Roberts WE, Henry M, Burgess C, et al. Laser treatment of skin of color for medical and aesthetic uses with a 650-microsecond Nd:YAG laser. J Drugs Dermatol. 2019.
8. Kesty K, Goldberg DJ. 650-microsecond 1064 nm Nd:YAG laser treatment of acne: a double-blind randomized control study. J Cosmet Dermatol. 2020.
9. Saedi N. Efficacy and tolerance of a 650-microsecond pulsed 1064 nm Nd:YAG laser for moderate to severe acne vulgaris. J Drugs Dermatol. 2024;23(11):957-964.
10. Dierickx C. Real-world evidence in acne management: a 50-dermatologist field study of the 650-microsecond 1064 nm Nd:YAG laser. Lasers Surg Med. 2024.
11. Grewal T, Saedi N, Ortiz A. A clinical evaluation of the 1064 nm Nd:YAG laser with a 650-microsecond pulse duration for the treatment of acne vulgaris.
12. Gold MH, et al. Treatment of moderate to severe acne and scars with a 650-microsecond 1064 nm laser and isotretinoin. J Drugs Dermatol. 2020.
13. Salameh F, Shumaker PR, Goodman GJ, et al. Energy-based devices for the treatment of acne scars: 2022 international consensus recommendations. Lasers Surg Med. 2022;54(1):10-26.
CLICK FOR MORE INFORMATION BELOW!
